Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ROGAINE EXTRA STRENGTH (FOR MEN) vs MEN'S ROGAINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Minoxidil is a potassium channel opener that hyperpolarizes vascular smooth muscle cells, leading to vasodilation. It also prolongs the anagen phase of hair follicles and increases hair follicle size, promoting hair growth.
Minoxidil is a potassium channel opener that increases cutaneous blood flow and stimulates hair follicles through vasodilation and direct mitogenic effects on dermal papilla cells, prolonging the anagen phase and increasing hair follicle size.
Treatment of androgenetic alopecia (male pattern baldness) in men
FDA-approved for the treatment of androgenetic alopecia (male pattern baldness) in men aged 18-49 with mild to moderate hair loss at the vertex (top of scalp).
1 m L of 5% minoxidil solution applied topically to the scalp twice daily.
Topical 5% solution: apply 1 m L to scalp twice daily. Max: 2 m L/day.
Terminal elimination half-life is approximately 4.2 hours (range 3.5–5.0 hours) in healthy adults. Clinical context: Maintains steady-state concentrations with twice-daily topical application without significant accumulation.
The terminal elimination half-life of minoxidil after topical administration is approximately 4.2 hours (range 2.5–4.7 hours) in patients with normal renal function. This short half-life necessitates twice-daily application to maintain steady-state concentrations for continuous hair growth stimulation.
Minoxidil is primarily metabolized by conjugation with glucuronic acid at the N-oxide position in the liver. CYP450 enzymes are minimally involved.
Minoxidil is primarily metabolized by conjugation with glucuronic acid (via UGT1A1) to form minoxidil N-glucuronide; also undergoes sulfation and minor oxidative metabolism.
Renal excretion of unchanged drug and metabolites accounts for approximately 95% of elimination. Fecal excretion is minimal (<3%).
Approximately 60% of topical minoxidil is absorbed systemically. The absorbed dose is primarily excreted via the kidneys as unchanged minoxidil and its glucuronide and sulfate conjugates. Renal excretion accounts for about 95% of elimination, with fecal excretion (~5%) being minor. Unabsorbed drug is eliminated in feces via desquamation and washing.
Approximately 20% bound to plasma proteins (primarily albumin).
Minoxidil is approximately 20% bound to plasma proteins (primarily albumin). Binding is low and not concentration-dependent over the therapeutic range.
Apparent volume of distribution is approximately 2.5 L/kg, indicating extensive distribution into total body water and tissues.
The apparent volume of distribution (Vd) of minoxidil after intravenous administration is approximately 3.3 L/kg (range 2.5–4.2 L/kg), indicating extensive distribution into tissues. This large Vd is consistent with its lipophilicity and penetration into hair follicles and skin.
Topical: systemic bioavailability is low (approximately 1.4% of applied dose) due to poor percutaneous absorption. Oral: approximately 50% (not indicated for this formulation).
Bioavailability of minoxidil from topical 5% solution is approximately 1.5% (range 0.3–4.5%) of the applied dose, based on urinary recovery. The 2% solution yields similar relative bioavailability (about 1.4%). Systemic absorption is minimal, with most drug remaining in the skin and hair follicles.
No dosage adjustment required for renal impairment; not systemically absorbed in significant amounts.
No dose adjustment required for topical use; systemic absorption minimal.
No dosage adjustment required for hepatic impairment; not systemically absorbed in significant amounts.
No dose adjustment required for topical use; systemic absorption minimal.
Safety and effectiveness in pediatric patients under 18 years have not been established.
Safety and efficacy not established in patients under 18 years; not recommended.
No specific dosage adjustment; use with caution due to potential for increased systemic absorption from thinner skin.
No specific dose adjustment; use same as adults but monitor for systemic effects due to possible skin atrophy and reduced renal function.
No FDA boxed warning.
None
Cardiovascular risks such as tachycardia, fluid retention, and pericardial effusion with topical use are rare but possible.,May cause hypotension if accidentally ingested.,Avoid contact with eyes and broken skin.,Discontinue if scalp irritation occurs.,Use with caution in patients with hypertension or underlying cardiovascular disease.
May cause hypotension if absorbed systemically; avoid use on broken or irritated scalp; discontinue if scalp irritation, redness, or burning occurs; not effective for receding hairlines; palpitations, edema, or dizziness may indicate systemic absorption; use caution in patients with cardiovascular disease or hypertension.
Hypersensitivity to minoxidil or any component of the formulation.,Concomitant use with other topical agents on the scalp.
Hypersensitivity to minoxidil or any component of the formulation; use in women (not indicated); use in patients with pheochromocytoma; application to a shaved or damaged scalp.
No known food interactions.
No known food interactions. Avoid grapefruit juice? Not reported with topical minoxidil. No dietary restrictions.
Topical minoxidil (Rogaine Extra Strength) is minimally absorbed (approximately 1.4% of applied dose). Animal studies show no teratogenicity at systemic exposures up to 4 times the human dose. Human data are insufficient; risk is considered low but cannot be excluded. Use only if clearly needed during pregnancy. No specific trimester risks identified.
Topical minoxidil (MEN'S ROGAINE) has limited systemic absorption; however, based on animal studies and case reports, it is classified as Pregnancy Category C. First trimester: No adequate human studies; animal studies show some fetal abnormalities at high doses. Second and third trimesters: Theoretical risk of fetal hypotension and altered hair growth; avoid use unless potential benefit outweighs risk.
Minoxidil is excreted in human milk following oral administration; however, following topical application, systemic absorption is minimal (1.4%). The M/P ratio is unknown. Because of the potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
Minoxidil is excreted into breast milk in low amounts; the milk-to-plasma (M/P) ratio is unknown. Systemic absorption from topical application is minimal (approximately 1.4-2%), but due to potential adverse effects (e.g., hypotension) in the nursing infant, it is generally not recommended during breastfeeding.
No dose adjustment is necessary. Pharmacokinetic changes in pregnancy (e.g., increased blood volume, altered skin perfusion) are not expected to significantly alter the minimal systemic absorption of topical minoxidil. Use standard dosing: 1 m L twice daily to the scalp.
No dosing adjustment is recommended for topical minoxidil during pregnancy due to minimal systemic exposure; however, use is generally avoided per precaution. Pharmacokinetic changes in pregnancy (e.g., increased volume of distribution, altered metabolism) are unlikely to be clinically significant given the route and low absorption.
Rogaine Extra Strength (5% minoxidil) is indicated for androgenetic alopecia in men. Onset of hair regrowth typically occurs after at least 4 months of twice-daily use; continued use is required to maintain effects. Discontinue if scalp irritation or unwanted facial hair growth occurs. Not effective for receding frontal hairline; primarily promotes vertex balding. May cause initial shedding of telogen hairs, which is a sign of efficacy.
Men's Rogaine contains minoxidil 5%, which is FDA-approved for androgenetic alopecia in men. Application requires direct scalp contact; avoid hair interference. Initial shedding may occur due to telogen phase synchronization. Response requires 4-6 months of twice-daily application; discontinuation leads to regrowth loss within 3-4 months. Adverse effects include contact dermatitis, hypertrichosis, and rare cardiovascular effects (tachycardia, edema) due to systemic absorption.
Apply 1 m L directly to the scalp in the affected area twice daily, not more often.,Wash hands thoroughly after each application.,Do not apply to wet hair or within 24 hours of using other scalp treatments.,Results may take 4 months or longer; continued use is necessary to maintain regrowth.,Initial hair shedding is normal and indicates new hair growth.,Avoid contact with eyes; if accidental contact occurs, rinse with cool water.
Apply twice daily to dry scalp, not to wet hair.,Use the dropper or spray directly onto the balding area; do not use more than 1 m L per dose.,Wash hands thoroughly after application.,Do not apply to other areas of the body to avoid unwanted hair growth.,Avoid contact with eyes, nose, or mucous membranes; rinse immediately with water if contact occurs.,Monitor for scalp irritation; discontinue if severe redness or itching occurs.,Consistency is key; missed doses reduce efficacy.,Hair loss may temporarily increase in first 2-6 weeks; this is normal.,Results are best visible after 4-6 months of regular use.,If no results after 1 year, discontinue use.,Do not use with other topical products on the scalp within 2 hours of application.,Avoid inhalation of spray; use in a well-ventilated area.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ROGAINE EXTRA STRENGTH (FOR MEN) vs MEN'S ROGAINE, answered by our medical review team.
ROGAINE EXTRA STRENGTH (FOR MEN) is a Hair Growth Agent that works by Minoxidil is a potassium channel opener that hyperpolarizes vascular smooth muscle cells, leading to vasodilation. It also prolongs the anagen phase of hair follicles and increases hair follicle size, promoting hair growth.. MEN'S ROGAINE is a Topical Hair Growth Agent that works by Minoxidil is a potassium channel opener that increases cutaneous blood flow and stimulates hair follicles through vasodilation and direct mitogenic effects on dermal papilla cells, prolonging the anagen phase and increasing hair follicle size.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ROGAINE EXTRA STRENGTH (FOR MEN) and MEN'S ROGAINE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ROGAINE EXTRA STRENGTH (FOR MEN) is: 1 m L of 5% minoxidil solution applied topically to the scalp twice daily.. The standard adult dose of MEN'S ROGAINE is: Topical 5% solution: apply 1 m L to scalp twice daily. Max: 2 m L/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ROGAINE EXTRA STRENGTH (FOR MEN) and MEN'S ROGAINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ROGAINE EXTRA STRENGTH (FOR MEN) is classified as Category C. Topical minoxidil (Rogaine Extra Strength) is minimally absorbed (approximately 1.4% of applied dose). Animal studies show no teratogenicity at systemic exposures up to 4 times the. MEN'S ROGAINE is classified as Category C. Topical minoxidil (MEN'S ROGAINE) has limited systemic absorption; however, based on animal studies and case reports, it is classified as Pregnancy Category C. First trimester: No . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.